A Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

Inclusion Criteria: * Adults (male or female) aged 18 years and older; * Participants with a serum potassium concentration \>5.0 mmol/L (serum potassium concentration will be measured using the i-STAT portable biochemical analyzer in screening period); * Participants who have negative pregnancy test result at screening and ensure the use of contraception during the trial; * Participants who understand and voluntarily sign the Informed Consent Form. Exclusion Criteria: * Participants who have a history of severe drug allergy, or are definitely allergic to the investigational product or its ingredients; * Participants who have pseudohyperkalemia, such as serum potassium increasing caused by hemolysis of blood samples due to improper blood- Page 3 of 8 collection methods (such as too tight pressure pulse band banding, too heavy local rubbing, repeated fist clenching-loosening hands), hemolysis of blood samples due to difficulty in venipuncture or trauma, and severe leukocytosis (\>50 × 10\^9/L) or thrombocytosis (\>500 × 10\^9/L); * Participants with acute hyperkalemia caused by conditions such as tumor lysis syndrome or hemolysis and so on; * Participants suffering from severe cerebrovascular diseases, such as cerebral infarction or cerebral hemorrhagic disease, or those who may have language disorder or delayed responses due to a history of cerebrovascular disease and thus are unable to communicate normally during screening; * Participants who have suffered from myocardial infarction, or have undergone interventional cardiac procedures or coronary artery bypass grafting for coronary atherosclerotic heart disease within 3 months prior to screening; or participants who have heart failure and are in cardiac function class IV (New York Heart Association, NYHA classification criteria) at screening; * Patients with cardiac arrhythmia requiring urgent treatment at screening, such as ventricular tachycardia, ventricular fibrillation, II-III degree atrioventricular block, severe bradycardia (heart rate \<40 bpm), or patients with significant prolongation of PR interval (PR interval prolonged to more than 0.25 seconds in the absence of atrioventricular block), decrease or disappearance of P wave amplitude, and widening of QRS wave (widening to more than 0.14 seconds in the absence of bundle branch block) indicated by the electrocardiogram at screening; * Patients who have previously undergone major gastrointestinal surgery such as subtotal gastrectomy, short bowel syndrome and other diseases affecting the normal peristalsis of the gastrointestinal tract; or patients with intractable constipation; * Patients who have received treatment with polypropylene exchange resin or sodium zirconium cyclosilicate and other similar drugs within 3 days before screening; * Patients who participated in other clinical trials of drugs or devices not approved for marketing within 3 months prior to the first dose; * Participants who are receiving dialysis; * Patients with severe hepatic impairment: serum alanine aminotransferase or aspartate aminotransferase more than 3 times the upper limit of normal; * Patients who are unable to complete this part of the trial as assessed by the investigator due to any other disease or psychiatric condition; or patients whose participation in the trial is assessed by the investigator as having a risk that far outweighs the benefit.